Haemonetics (HAE) Stock: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$102.53
1.47 (1.45%)
â˛
5d:
-0.32%
30d:
+12.25%
90d:
+28.41%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 11.6% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HAE is fairly priced but lacks strong directional signals. At 11.6% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$95.41
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$59.24
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $102.53, which is considered fair relative to its 30-day fair value range of $89.67 to $106.94. From a valuation perspective, the stock is trading at a premium (Forward PE: 19.1) compared to its historical average (13.8). At these levels, the market is pricing in 11.6% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $100.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HAE scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HAE is in a strong uptrend. The price is currently testing key support at $100.53. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: HAE scores 8/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$89.67 -
$106.94
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
40.5%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (8/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($108.40)
- BEARISH: Market expects 11.6% growth - appears too optimistic based on history
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$89.67 -
$106.94
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$100.53
Resistance Level
$105.61
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.10
Wall Street Target
$108.40
(+7.3%)
Revenue Growth (YoY)
5.6%
Earnings Growth (YoY)
2.9%
Profit Margin
7.1%
Valuation Premium vs History
+11.6% premium
PE vs Historical
19.1 vs 13.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+11.6%
(market-implied from PE analysis)
1-Year Target
$112.78
(+12%)
2-Year Target
$125.87
(+25%)
3-Year Target
$140.47
(+39%)
3-Yr Target (if PE normalizes)
(PE: 19â14)
PE COMPRESSION
$101.49
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 7.0%)
$130.90
(+30%)
Base:
(SPY PE: 19.1, Growth: 7.0%)
$123.95
(+23%)
Bear:
(PE: 13.8, Growth: 7.0%)
$89.56
(-11%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (50x PE), but valuation improves significantly next year (19x PE) as earnings recover.
Trailing PE: 49.84 | Current EPS (TTM): $2.07
Bull Case
$226.95
(+125%)
Analyst growth 100.0%, PE expands to 54.8
Base Case
$206.32
(+104%)
Market implied 100.0%, PE stable at 49.8
Bear Case
$70.15
(-31%)
Severe decline -20.0%, PE contracts to 42.4
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 11, 2026 3:42 PM ET
Data refreshes hourly during market hours. Next update: 4:42 PM
Data refreshes hourly during market hours. Next update: 4:42 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$383 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
